Infertility
Conditions
Keywords
PCOS and normal ovulatory patients, aneuploidy, in-vitro maturation of oocytes
Brief summary
A single centre randomised controlled trial investigating the influence of a novel prematuration system (PMS) using a phosphodiesterase-3 inhibitor for in-vitro maturation of oocytes - pilot study.
Interventions
PROCEDUREprematuration culture
The aneuploidy rate and the developmental potential of embryos obtained from PDE3 inhibitor-treated oocytes (a prolonged IVM (PMC)) in comparison to conventional IVM will be analysed. It is intended to assess the nuclear and cytogenetic constitution of the obtained embryos.
Sponsors
Universitair Ziekenhuis Brussel
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 35 Years
Healthy volunteers
Yes
Inclusion criteria
* healthy volunteers, either with PCOS/PCOS-like ovaries, or with normal ovaries, who undergo oocyte donation for research * AFC at least 10 * AMH: \> 5 μg/L * Female age \< 36 years
Exclusion criteria
* major uterine or ovarian abnormalities
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of aneuploidy rate by fluorescence in situ hybridisation (FISH) technique in 6 to 8 cell embryos from prolonged (PMC) IVM compared to conventional IVM on sibling oocytes. | 3 days after egg retrieval |
Secondary
| Measure | Time frame |
|---|---|
| Implantation potential of embryos from conventional IVM performed on Type II COC. Efficiency of both maturation systems in obtaining blastocysts. Endometrium quality in IVM cycles. | 7 days after egg retrieval |
Countries
Belgium
Outcome results
None listed